Anna Hockaday
YOU?
Author Swipe
View article: Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia Open
With extended follow-up and increased enrollment, our trial showed that undetectable MRD and extended progression-free survival were more common with ibrutinib-venetoclax than with ibrutinib alone or FCR. The results for overall survival w…
View article: Optimising the Duration of Therapy for Newly Diagnosed Transplant Ineligible Patients - Analysis of Long Term Follow up Data from the UK MRA Myeloma XI Trial
Optimising the Duration of Therapy for Newly Diagnosed Transplant Ineligible Patients - Analysis of Long Term Follow up Data from the UK MRA Myeloma XI Trial Open
Introduction Ongoing therapy to progression has become a standard of care for newly diagnosed myeloma (NDMM) patients but this carries with it an increased burden of treatment administration and potential side effects. This may be of parti…
View article: Final Analysis of the Randomised UK MRA Myeloma XI+ Trial Examining Krdc (carfilzomib, lenalidomide, dexamethasone and cyclophosphamide) As Induction Therapy for Newly Diagnosed Multiple Myeloma Patients
Final Analysis of the Randomised UK MRA Myeloma XI+ Trial Examining Krdc (carfilzomib, lenalidomide, dexamethasone and cyclophosphamide) As Induction Therapy for Newly Diagnosed Multiple Myeloma Patients Open
Introduction The UKMRA/NCRI Myeloma XI+ phase III randomized trial for NDMM patients compared intensified induction with a carfilzomib containing quadruplet (KRdc) vs a response-adapted approach of sequential triplet therapies. An interim …
View article: IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study
IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study Open
Introduction: Ibrutinib (I), irreversible Btk inhibitor, and venetoclax (V), Bcl-2 inhibitor, have both improved outcomes in CLL in numerous clinical trials compared to chemoimmunotherapy. V has been approved for CLL alone or combined with…
View article: Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial
Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial Open
Cancer Research UK, Takeda Oncology.
View article: Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease Open
MRD-directed ibrutinib-venetoclax improved progression-free survival as compared with FCR, and results for overall survival also favored ibrutinib-venetoclax. (Funded by Cancer Research UK and others; FLAIR ISRCTN Registry number, ISRCTN01…
View article: Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study
Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study Open
Introduction: Ibrutinib (I), an irreversible Btk inhibitor, and venetoclax (V), a Bcl-2 inhibitor, improve CLL outcomes in trials compared to chemoimmunotherapy. I and V target two key pathophysiological pathways in CLL and should be syner…
View article: Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients
Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients Open
Background The NCRI FLAIR trial confirmed ibrutinib + rituximab (IR) improved progression free survival (PFS) over FCR in untreated CLL. Durable responses are achieved on continuous Bruton's tyrosine kinase inhibitor (BTKi) therapy, but ac…
View article: Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial
Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial Open
CONCLUSIONS Time-limited treatments for CLL are under investigation but the optimal target for treatment cessation is not fully clear. Bone marrow (BM) measurable residual disease (MRD) is usually the most sensitive measure but would be to…
View article: Data from <i>TP53</i> Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia
Data from <i>TP53</i> Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia Open
Purpose:In chronic lymphocytic leukemia (CLL), TP53 mutations are associated with reduced survival and resistance to standard chemoimmunotherapy (CIT). Nevertheless, the clinical impact of subclonal TP53 mutations below 10% to 15% variant …
View article: Data from <i>TP53</i> Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia
Data from <i>TP53</i> Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia Open
Purpose:In chronic lymphocytic leukemia (CLL), TP53 mutations are associated with reduced survival and resistance to standard chemoimmunotherapy (CIT). Nevertheless, the clinical impact of subclonal TP53 mutations below 10% to 15% variant …
View article: Supplementary Data from <i>TP53</i> Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia
Supplementary Data from <i>TP53</i> Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia Open
Supplemental Material and Methods
View article: The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma <scp>XI’</scp>, a multicentre, open‐label, randomised, phase III trial
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma <span>XI’</span>, a multicentre, open‐label, randomised, phase III trial Open
Summary Lenalidomide is an effective maintenance agent for patients with myeloma, prolonging first remission and, in transplant eligible patients, improving overall survival (OS) compared to observation. The ‘Myeloma XI’ trial, for newly d…
View article: Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial
Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial Open
Introduction Multiple myeloma is a plasma cell malignancy that accounts for 1%–2% of newly diagnosed cancers. At diagnosis, approximately 20% of patients can be identified, using cytogenetics, to have inferior survival (high-risk). Additio…
View article: Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the <scp>UK National Cancer Research Institute</scp> phase <scp>II</scp>/<scp>III GALACTIC</scp> trial
Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the <span>UK National Cancer Research Institute</span> phase <span>II</span>/<span>III GALACTIC</span> trial Open
Summary The GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In chronic lymphocytic leukaemia (CLL) (GALACTIC) was a seamless phase II/III trial designed to test whether consolidation with obinutuzumab is safe and eradicat…
View article: Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study
Association of genetic variants with patient reported quality of life and pain experience in patients in the UK NCRI Myeloma X Relapse [Intensive]) trial; an exploratory study Open
The Myeloma X trial provided a platform to explore genetics in relation to systematic assessment of patient-reported outcomes at key points during salvage treatment in multiple myeloma (MM) patients. Blood DNA was obtained in 191 subjects …
View article: P673: DEPLETION AND RECOVERY OF NORMAL B-CELLS DURING AND AFTER TREATMENT WITH CHEMOIMMUNOTHERAPY, IBRUTINIB OR VENETOCLAX.
P673: DEPLETION AND RECOVERY OF NORMAL B-CELLS DURING AND AFTER TREATMENT WITH CHEMOIMMUNOTHERAPY, IBRUTINIB OR VENETOCLAX. Open
Background: Infectious complications are a major cause of morbidity and mortality in Chronic Lymphocytic Leukaemia (CLL). Therapeutic approaches that deplete CLL cells also affect normal B-cells. Optimal treatment would result in eradicati…
View article: S145: THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS IN A HIGH RATE OF MRD NEGATIVITY IN PREVIOUSLY UNTREATED CLL: THE RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE PHASE III NCRI FLAIR TRIAL
S145: THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS IN A HIGH RATE OF MRD NEGATIVITY IN PREVIOUSLY UNTREATED CLL: THE RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE PHASE III NCRI FLAIR TRIAL Open
Background: Ibrutinib (I) and venetoclax (V) improve outcome in CLL. I rarely eradicates measurable residual disease (MRD), whereas V (alone or with anti-CD20) can eradicate MRD permitting time limited therapy. Small studies suggest synerg…
View article: <i>F</i> railty-adjusted therapy <i>i</i> n <i>T</i> ransplant <i>N</i> on- <i>E</i> ligible patient <i>s</i> with newly diagno <i>s</i> ed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial
<i>F</i> railty-adjusted therapy <i>i</i> n <i>T</i> ransplant <i>N</i> on- <i>E</i> ligible patient <i>s</i> with newly diagno <i>s</i> ed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial Open
Introduction Multiple myeloma is a bone marrow cancer, which predominantly affects older people. The incidence is increasing in an ageing population. Over the last 10 years, patient outcomes have improved. However, this is less apparent in…
View article: Long‐term follow‐up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide‐based chemoimmunotherapy in the frontline <scp>ADMIRE</scp> and <scp>ARCTIC</scp> trials: A comprehensive assessment of prognostic factors
Long‐term follow‐up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide‐based chemoimmunotherapy in the frontline <span>ADMIRE</span> and <span>ARCTIC</span> trials: A comprehensive assessment of prognostic factors Open
Ten-year follow-up
View article: Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials project
Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials project Open
Background Adaptive designs offer great promise in improving the efficiency and patient-benefit of clinical trials. An important barrier to further increased use is a lack of understanding about which additional resources are required to c…
View article: <i>TP53</i> Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia
<i>TP53</i> Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia Open
Purpose: In chronic lymphocytic leukemia (CLL), TP53 mutations are associated with reduced survival and resistance to standard chemoimmunotherapy (CIT). Nevertheless, the clinical impact of subclonal TP53 mutations below 10% to 15% variant…
View article: COSMIC, chemotherapy plus ofatumumab at standard or mega‐dose in chronic lymphocytic leukaemia, a phase II randomised study
COSMIC, chemotherapy plus ofatumumab at standard or mega‐dose in chronic lymphocytic leukaemia, a phase II randomised study Open
Chemoimmunotherapy (CIT) comprising cytotoxics and anti-CD20 monoclonal antibodies (mab) has long been the therapeutic mainstay for chronic lymphocytic leukaemias (CLL). The CD20 mabs commonly employed are rituximab, obinutuzumab and ofatu…
View article: Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial Open
Background Carfilzomib is a second-generation irreversible proteasome inhibitor that is efficacious in the treatment of myeloma and carries less risk of peripheral neuropathy than first-generation proteasome inhibitors, making it more amen…
View article: Additional file 2 of Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials project
Additional file 2 of Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials project Open
Additional file 2. Resource template pre-revision.
View article: Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma
Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma Open
Summary Predicting patient outcome in multiple myeloma remains challenging despite the availability of standard prognostic biomarkers. We investigated outcome for patients relapsing early from intensive therapy on NCRI Myeloma XI. Relapse …